Doherty Clinical Trials launches the #mRNA Platform Incubator Network

At the recent annual AusBiotech conference held in Brisbane, Australia, Moderna announced the highly anticipated launch of the #mRNA Platform Incubator Network.

‍

Doherty Clinical Trials are proud to be partnering with Moderna on this pioneering initiative, which aims to advance mRNA medicine, foster scientific excellence in clinical translation in Australia and further the therapeutic potential of the mRNA platform.

‍

The Platform Incubator Network brings together Australia’s leading minds in mRNA research including our team at Doherty Clinical Trials, Monash University and Monash Institute of Pharmaceutical Sciences (MIPS), the Peter Doherty Institute of Infection and Immunity – a joint venture of The University of Melbourne and The Royal Melbourne Hospital, Peter MacCallum Cancer Centre and the Murdoch Research Children’s Institute.

‍

CEO, Dr Andrew Brockway has said “At Doherty Clinical Trials, we're excited to join the mRNA Platform Incubator Network with Moderna and other outstanding Australian institutions. This unique collaboration is a significant step forward in the realm of mRNA medicine research right here in Australia, and we're proud to contribute our expertise in infectious disease clinical trials to help accelerate the translation of mRNA research into practical, life-changing applications. This network of experts has the potential to drive real-world solutions that can improve healthcare outcomes and will be contributing to meaningful medical advancements globally, which is exactly why Doherty Clinical Trials was established.”

‍

Based out of Moderna’s Regional Research Centre in Melbourne, the Platform Incubator Network will allow for regular cross-functional collaboration, exploration and execution of translational research projects, contribute new insights to the broader scientific and regulatory community through publications and discussions and support the development of the next generation of researchers.